The following reader question came in response to the column “Critical Guidance for Complying With Anesthesia Infection Control Rules,” which features insight from Clifford Gevirtz, MD, an ...
"TECVAYLI is the only BCMA-targeted immune-based therapy with weight-based dosing. Today's approval of biweekly dosing for eligible patients will further enable clinicians to meet the individual needs ...
NEW HAVEN, Conn.--(BUSINESS WIRE)--Rallybio Corporation (Nasdaq: RLYB) today announced preliminary Phase 1 multiple ascending dose (MAD) data for RLYB116, an innovative, long-acting, low volume ...
NEW YORK, NY / ACCESS Newswire / August 21, 2025 / Protagenic Therapeutics, Inc. (PTIX), a biopharmaceutical company developing novel neuro-active peptide therapies, today announced completion of ...
This mercury-containing compound, used as a vaccine preservative, is commonly used in lower-income countries — and deemed ...
The new biweekly dosing regimen for Tecvayli is intended for patients with RRMM who have achieved and maintained a complete response or better for a minimum of 6 months. The Food and Drug ...
BETHESDA, Md., July 09, 2024 (GLOBE NEWSWIRE) -- Gain Therapeutics, Inc. (Nasdaq: GANX) (“Gain”, or the “Company”), a clinical-stage biotechnology company leading the discovery and development of the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results